A method for efficiently expanding human mucosal-associated constant T cells in vitro
By using 5-OP-RU and human interleukin-like cytokines combined stimulation, the efficient expansion of human peripheral blood MAIT cells was successfully achieved, solving the problem of low amplification efficiency in the prior art, and to study MAIT cells in human diseases The role of .
Patent Information
- Application Number
- CN202211393019.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-11-08
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2042-11-08
AI Technical Summary
The prior art is difficult to effectively expand human mucosal-related constant T cells in vitro, resulting in research difficulties, especially the role of MAIT cells in human diseases has not been fully explored.
5-OP-RU, recombinant human interleukin-12 or recombinant human interleukin-1b and recombinant human interleukin-23 combined with immunocyte serum supplements and antibiotics, through specific culture steps and flow Cell detection achieves efficient expansion of MAIT cells, with a cell ratio exceeding 70%.
The successful increase of the MAIT cell ratio from less than 5% to more than 70% provides a basis for studying the biological behavior and potential immunotherapy of MAIT cells, and is suitable for the research of infectious, autoimmune, metabolic diseases and tumors.
Smart Images

Figure CN115747158B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of cell culture, and in particular relates to a method for efficiently amplifying human mucosa-associated constant T cells in vitro. Background Art
[0002] Mucosa-associated invariant T (MAIT) cells are a type of innate T cells that are widely distributed in mucosal tissues such as the liver, lungs, and gastrointestinal tract, as well as in peripheral blood (PB). MAIT cells have the function of directly clearing bacteria. In addition, they play many immunomodulatory roles with their pluripotency, such as fighting viral / bacterial infections, maintaining mucosal immune homeostasis, promoting tissue repair, and anti-tumor. However, as an important means of scientific experiments, experimental mice and rats are extremely difficult to use for further research due to their low MAIT cell ratio. In addition, the phenotype and biological functions of MAIT cells in mice and rats are not completely equivalent to those of human MAIT cells. Due to the lack of effective means to expand human tissue MAIT cells in vivo and in vitro, many researchers can only superficially analyze the correlation between MAIT cells and many diseases, including infectious diseases (such as sepsis), autoimmune diseases (inflammatory bowel disease, multiple sclerosis), and metabolic diseases (such as diabetes, fatty liver disease). If we want to further study the role of MAIT cells in human diseases, it is imperative to reinfuse MAIT cells. Therefore, it is urgent to expand MAIT cells in vitro and then use them in medical research. Therefore, it is meaningful to determine an effective method to isolate, culture, and expand MAIT cells from human peripheral blood (or other tissues).
[0003] Finding a powerful, specific antigen for human tissue MAIT cells will help to specifically proliferate human tissue MAIT cells in vitro, thereby better understanding the biological functions of MAIT cells and providing new targets for the treatment of multiple diseases.
[0004] When the applicant previously studied bat host immunity, he used 5-OP-RU, the most powerful specific antigen of MAIT cells, for in vitro stimulation and successfully proliferated MAIT cells in the peripheral blood of bats in vitro. Although both are mammals, there are huge differences between humans and bats in terms of the body's immune system response and the T cell receptor sequences of MAIT cells. Not only that, the ratio and function of antigen-presenting cells (such as monocytes, used to present 5-OP-RU to MAIT cells) are not uniform in humans and bats. Based on the fact that the MR1 sequence is highly conserved among mammals, whether 5-OP-RU can be combined with inflammatory factors to stimulate and proliferate human-derived MAIT cells in vitro, while ensuring their activity and biological functions for use in human physiology or disease research, remains to be further verified. Summary of the invention
[0005] In order to address the deficiencies in the prior art, the present invention aims to provide a method for efficiently amplifying human mucosal-associated constant T cells in vitro.
[0006] The specific technical solutions of the present invention are as follows:
[0007] In one aspect, the present invention provides a method for efficiently amplifying human mucosal-associated constant T cells in vitro, comprising the following steps:
[0008] 1) Resuspending human peripheral blood mononuclear cells or human mucosal-associated constant T cells in a T cell expansion medium that does not contain exogenous substances and serum, and adding immune cell serum supplements, recombinant human interleukin-12 or recombinant human interleukin-1b and recombinant human interleukin-23 to the culture system for culturing;
[0009] 2) On days 0, 5 and 10, 5-OP-RU was added to the culture system for stimulation, the T cell expansion medium was replaced every 2 to 3 days, and the immune cell serum supplement, recombinant human interleukin-12 or recombinant human interleukin-1b and recombinant human interleukin-23 at the same concentration as in step 1) were supplemented. On the 11th day of expansion, dead cells were removed, and the MAIT cell ratio was detected by flow cytometry. When the cell ratio of human mucosal-associated invariant T cells was >70%, the cells were collected.
[0010] Furthermore, the human mucosa-associated constant T cells are isolated from human peripheral blood or tissues and organs.
[0011] Furthermore, gentamicin and Normocin are also added to the culture system in step 1);
[0012] Preferably, the concentration of gentamicin is 50 μg / mL;
[0013] Preferably, the concentration of Normocin is 100 μg / mL.
[0014] Furthermore, in the culture system of step 1), the final concentration of the immune cell serum supplement is 8%;
[0015] The concentration of the recombinant human interleukin-12 or recombinant human interleukin-1b is 5 to 10 ng / mL;
[0016] The concentration of the recombinant human interleukin-23 is 5-10 ng / mL.
[0017] Further, the final concentration of 5-OP-RU added to the culture system in step 2) is 2 to 10 nM;
[0018] The 5-OP-RU is diluted using T cell expansion medium that does not contain exogenous substances and serum;
[0019] The process of diluting the 5-OP-RU and adding it to the culture system is controlled to take no longer than 5 minutes;
[0020] Preferably, the final concentration of 5-OP-RU added is 10 nM.
[0021] Furthermore, the method also includes purifying the collected cells using Vα7.2 magnetic beads.
[0022] Another aspect of the present invention provides human mucosa-associated constant T cells obtained by expansion of the method.
[0023] Another aspect of the present invention provides the use of the human mucosal-associated constant T cells in the preparation of a drug for treating one of the following diseases, characterized in that the disease includes:
[0024] 1) Infectious diseases;
[0025] 2) Autoimmune diseases;
[0026] 3) Metabolic diseases;
[0027] 4) Tumor.
[0028] Further, the infectious diseases include sepsis, viral and bacterial infections;
[0029] The autoimmune diseases include inflammatory bowel disease and multiple sclerosis;
[0030] The metabolic diseases include diabetes and fatty liver disease.
[0031] Another aspect of the present invention provides the use of the human mucosa-associated constant T cells as a cell model in studying the role of human mucosa-associated constant T cells in human diseases.
[0032] Furthermore, the human diseases include infectious diseases, autoimmune diseases, metabolic diseases and tumors;
[0033] Preferably, the infectious diseases include sepsis, viral and bacterial infections;
[0034] The autoimmune diseases include inflammatory bowel disease and multiple sclerosis;
[0035] The metabolic diseases include diabetes and fatty liver disease.
[0036] The beneficial effects of the present invention are:
[0037] The present invention provides a method for efficiently expanding human mucosal-associated invariant T cells in vitro, wherein 5-(2-oxopropylideneamino)-6-(d-ribosyl)uracil (5-OP-RU), recombinant human interleukin-12 or recombinant human interleukin-1b and recombinant human interleukin-23 are used to synergistically stimulate human peripheral blood mononuclear cells or MAIT cells. For subjects whose MAIT cell ratio is less than 5%, in vitro expansion can also be effectively performed, and the MAIT cell ratio can exceed 70% on the 10th day, thereby providing a basis for studying the biological behavior of MAIT cells under physiological and pathological conditions, as well as future MAIT cell-mediated immunotherapy methods. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Figure 1 The ratio of MAIT cells in the cells collected for Example 1 and the comparative example.
[0039] Figure 2 This is the magnetic bead sorting result of Example 2. DETAILED DESCRIPTION
[0040] In order to understand the present invention more clearly, the present invention is further described with reference to the following examples and accompanying drawings. The examples are only used for explanation and are not intended to limit the present invention in any way. In the examples, each raw material reagent is commercially available, and the experimental methods without specifying specific conditions are conventional methods and conventional conditions well known in the art, or according to the conditions recommended by the instrument manufacturer.
[0041] Abbreviations and English meanings
[0042]
[0043] In the present invention, 5-OP-RU was synthesized by Wuxi WuXi AppTec Co., Ltd. with reference to the synthesis method in the published literature (MakJY et al. Nat Commun 2017. PMID: 28272391), and the purity of the synthesized 5-OP-RU was 90%.
[0044] Example 1
[0045] This example describes in detail a method for efficiently expanding human mucosal-associated invariant T cells in vitro, and the steps are as follows:
[0046] Human peripheral blood mononuclear cells (usually 1*10^7 cells per tube) stored in cryopreservation tubes were resuspensed, and the MAIT cell ratio in the human peripheral blood mononuclear cells was less than 5%. The cells were resuspended in T cell expansion medium (provided by Stem Cell, USA, catalog number: 10981) without exogenous substances and serum, and supplemented with 8% final concentration of immune cell serum supplement (provided by Thermo Fisher, USA, catalog number: A2596101), 5ng / mL recombinant human IL-12 or IL-1b (provided by R&D, USA) and 5ng / mL recombinant human IL-23 (provided by R&D, USA). The culture system also contains 50μg / mL gentamicin and 100μg / mL Normocin (provided by InvivoGen, USA). The purpose of adding gentamicin and Normocin to the culture system is to avoid microbial contamination such as bacteria and mycoplasma. The culture system was cultured in an incubator at 37°C and 5% CO2. On days 0, 5, and 10, 5-OP-RU was added to the culture system, and peripheral blood mononuclear cells were stimulated with 5-OP-RU at a final concentration of 10 nM. The culture medium (containing immune cell serum supplements and cytokines at the above concentrations) was replaced every 2 days. On the 11th day of expansion, dead cells were removed by gradient density centrifugation. The MAIT cell ratio was detected by flow cytometry. When the MAIT cell ratio was >70%, the cells could be used for downstream experiments.
[0047] When amplifying human MAIT cells in vitro, since 5-OP-RU is relatively stable in dimethyl sulfoxide solution but can be quickly converted into inactive dioxotetrahydropteridine when in contact with water, it should be diluted with T cell expansion medium in a very short time (usually no more than 5 minutes) and added to the amplification system.
[0048] Comparative Example
[0049] The difference between the comparative example and Example 1 is that 5 ng / mL of recombinant human IL-12 or IL-1b and 5 ng / mL of recombinant human IL-23 are replaced by 5 ng / mL of recombinant human IL-2 (provided by R&D Company, USA) and 5 ng / mL of recombinant human IL-7 (provided by R&D Company, USA). The other operation steps are the same as those in Example 1.
[0050] The ratio of MAIT cells in the cells collected from Example 1 and the comparative example is as follows Figure 1. MAIT cell ratio on day 0: 3.89%; MAIT cell ratio on day 5: 11.8% (IL-2+IL-7), 32.6% (IL-1b+IL-23), 16.8% (IL-12+IL-23); MAIT cell ratio on day 10: 13.4% (IL-2+IL-7), 71.5% (IL-1b+IL-23), 79.6% (IL-12+IL-23). By using the recombinant human IL-12 or IL-1b and recombinant human IL-23 of the present invention combined with 5-OP-RU stimulation, the MAIT ratio on day 10 alone can exceed 70% for downstream experiments.
[0051] The applicant previously used 5-OP-RU, IL-2 and IL-7 for stimulation and found that only subjects with a higher MAIT cell ratio (>5%) can be effectively expanded in vitro, that is, the MAIT cell ratio on the 10th day exceeds 70%. For subjects with a MAIT cell ratio of less than 5%, in vitro expansion cannot be effectively performed, that is, the MAIT cell ratio on the 10th day is less than 70%. However, the average MAIT cell ratio of healthy people is only 3%. For subjects with a MAIT cell ratio of less than 5%, the in vitro stimulation using 5-OP-RU, IL-1b or IL-12 and IL-23 of the present invention can effectively perform in vitro expansion, which more effectively guarantees the source of cells.
[0052] Example 2
[0053] In a specific embodiment, Vα7.2 magnetic beads (SiaWR et al., STAR Protoc. 2021; PMID: 34041501) can be used to purify MAIT cells to further improve the purity of MAIT cells. In this example, PE-labeled Vα7.2 antibodies were used to perform magnetic bead sorting on the cells collected in Example 1, and the purity of MAIT cells could reach more than 90% (i.e., CD161-FITC high expression and Vα7.2-PE positive cell population) (e.g. Figure 2 ).
[0054] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.
Claims
1. A method for efficiently amplifying human mucosal-associated constant T cells in vitro, characterized in that: The steps include: 1) Resuspending human peripheral blood mononuclear cells in a T cell expansion medium that does not contain exogenous substances and serum, and adding ① or ② to the culture system for culturing, wherein ① is an immune cell serum supplement, recombinant human interleukin-12 and recombinant human interleukin-23, and ② is an immune cell serum supplement, recombinant human interleukin-1b and recombinant human interleukin-23; 2) On days 0, 5, and 10, 5-OP-RU was added to the culture system for stimulation. The T cell expansion medium was replaced every 2-3 days and supplemented with ① or ② at the same concentration as in step 1). On day 11 of expansion, dead cells were removed and the MAIT cell ratio was detected by flow cytometry. When the cell ratio of human mucosal-associated invariant T cells was >70%, the cells were collected.
2. The method according to claim 1, characterized in that The human mucosal-associated constant T cells are isolated from human peripheral blood or tissues and organs.
3. The method according to claim 1, characterized in that: Gentamycin and Normocin are also added to the culture system in step 1).
4. The method according to claim 3, characterized in that The concentration of gentamicin is 50 μg / mL.
5. The method according to claim 3, characterized in that: The concentration of Normocin is 100 μg / mL.
6. The method according to claim 1, characterized in that In the culture system of step 1), the final concentration of the immune cell serum supplement is 8%; The concentration of the recombinant human interleukin-12 is 5-10 ng / mL; The concentration of the recombinant human interleukin-1b is 5-10 ng / mL; The concentration of the recombinant human interleukin-23 is 5-10 ng / mL.
7. The method according to claim 1, characterized in that Step 2) The final concentration of 5-OP-RU added to the culture system is 2~10 nM; The 5-OP-RU is diluted using T cell expansion medium that does not contain exogenous substances and serum; The process of diluting 5-OP-RU and adding it to the culture system is controlled to take no longer than 5 minutes.
8. The method according to claim 1, characterized in that: Step 2) The final concentration of 5-OP-RU added to the culture system is 10 nM.
9. The method according to claim 1, characterized in that: The method also includes purifying the collected cells using Vα7.2 magnetic beads.
